Regulatory Requirements For Biotechnological Products As Per CDSCO In India Comparison With USFDA

REVIEW ARTICLE Am. J. PharmTech Res. 2025; 15(05) ISSN: 2249-3387 Please cite this article as: Kumar A et al., Regulatory Requirements For Biotechnological Products As Per CDSCO In India Comparison With USFDA. American Journal of PharmTech Research 202 5 . Regulatory Requirements For Biotechnological Products As Per CDSCO In India Comparison With USFDA Dr. Ashok Kumar P*, Shivagangothri M, Kusuma K, Vanitha A, Chinmay D R, Chinthan SB Department of Regulatory Affairs, Sree Siddaganga College of Pharmacy, 1 st Left Cross, 3rd Block, Mahalakshmi Nagar, Near Railway Gate, 80 feet Road, Batwadi, Tumkur-572103, Karnataka, India. ABSTRACT Biotechnological products have transformed modern medicine by providing targeted and innovative therapies, including recombinant proteins, monoclonal antibodies, gene therapies, and vaccines, forming the foundation of precision medicine. However, their biological complexity and structural variability necessitate stringent regulatory oversight to ensure safety, efficacy, and quality. This study presents a comparative analysis of regulatory frameworks governing biotechnological products in India and the United States. In India, the Central Drugs Standard Control Organization (CDSCO) serves as the apex regulatory authority, implementing guidelines under the Drugs and Cosmetics Act of 1940. It mandates rigorous preclinical evaluations, phased clinical trials, adherence to Good Manufacturing Practices (GMP), and robust post-marketing surveillance to ensure product safety and therapeutic benefit. Conversely, the United States Food and Drug Administration (US FDA) regulates biotechnological products under the Public Health Service (PHS) Act and the Food, Drug, and Cosmetic (FD&C) Act. A distinctive feature of the US system is the Biologics License Application (BLA), which requires extensive clinical trials, comprehensive pharmacovigilance, and stringent GMP compliance, reflecting a strong emphasis on scientific validation and patient safety. The comparative analysis highlights key differences in approval timelines, regulatory pathways, clinical data requirements, and pharmacovigilance mechanisms. While CDSCO focuses on accessibility and affordability within India, the US FDA prioritizes exhaustive scientific evaluation and global standardization. Understanding these regulatory nuances is essential for pharmaceutical companies to streamline product development, ensure compliance, and foster public trust. This study underscores the need for harmonization and mutual recognition of standards to accelerate global patient access to life-saving biotechnological therapies. Keywords: CDSCO, FDA, biotechnological products, India USA. *Corresponding Author Email: [email protected] Received 08 September 2025, Accepted 22 September 2025 Journal home page: http://www.ajptr.com/ Kumar et. al., Am. J. PharmTech Res. 2025;15(05) ISSN: 2249-3387 www.ajptr.com 100 INTRODUCTION Biotechnology has emerged as one of the most transformative scientific disciplines of the 21st century, with applications spanning healthcare, agriculture, industry, and environmental management. In particular, biotechnological products-often referred to as biologics, have reshaped modern medicine through the development of vaccines, therapeutic proteins, monoclonal antibodies, and advanced therapies such as gene and cell-based treatments. Unlike conventional small-molecule drugs, these products are derived from living systems using tools such as recombinant DNA technology, hybridoma techniques, and genetic engineering, which allow precise targeting of molecular pathways involved in disease1. The healthcare sector represents the largest share of biotechnology applications. Recombinant human insulin, the first biopharmaceutical approved in the 1980s, demonstrated the potential of engineered proteins to replace natural hormones. Since then, advances such as monoclonal antibodies, immune modulators, and growth factors have become integral to the treatment of cancer, autoimmune diseases, and genetic disorders. Recent developments in mRNA and recombinant vaccines, particularly during the COVID-19 pandemic, highlight the speed and adaptability of biotechnology in responding to emerging health threats. Beyond medicine, biotechnology contributes to agriculture and industry by enhancing crop yields, producing safer animal vaccines, enabling environmentally sustainable manufacturing, and introducing diagnostic innovations. Applications in molecular testing, pharmacogenomics, and CRISPR-based genome editing further demonstrate its role in early disease detection, personalized medicine, and next-generation therapies2. Despite remarkable progress, biotechnological products face challenges such as high manufacturing costs, regulatory complexity, and unequal access to therapies across regions. Addressing these issues is critical to fully realizing their global impact. The aim of this article is to review the development, classification, and applications of biotechnological products, with particular emphasis on their role in healthcare and their potential to transform disease prevention, diagnosis, and treatment. Overview of CDSCO in India The Central Drugs Standard Control Organization (CDSCO), functioning under the Directorate General of Health Services, Ministry of Health and Family Welfare, serves as the National Regulatory Authority (NRA) of India. Headquartered in New Delhi, with multiple zonal, subzonal, and port offices as well as central laboratories, CDSCO enforces the Drugs and Cosmetics Kumar et. al., Am. J. PharmTech Res. 2025; 15(05) ISSN: 2249-3387 101 www.ajptr.com Act, 1940 and Rules, 1945 to regulate the safety, efficacy, and quality of drugs, cosmetics, and biological products across the country3. The major functions of CDSCO include the approval of new drugs, vaccines, recombinant products, and biosimilars; regulation and monitoring of clinical trials; granting licenses for the manufacture and import of specified categories such as blood banks, vaccines, large-volume parenterals, and r-DNA products; and oversight of pharmacovigilance activities to ensure postmarketing safety. In addition, CDSCO coordinates with State Drug Control Authorities to ensure uniformity in the enforcement of regulatory provisions nationwide. Beyond these regulatory roles, CDSCO aims to safeguard public health by promoting transparency, accountability, and consistency in its decision-making. It also focuses on encouraging research and development in the pharmaceutical and biotechnology sectors while fostering a science-based regulatory framework that is globally aligned and responsive to innovation. In the case of biotechnological products, CDSCO functions alongside several other regulatory bodies. The Review Committee on Genetic Manipulation (RCGM) under the Department of Biotechnology oversees biosafety during research and preclinical evaluation of recombinant products. The Genetic Engineering Appraisal Committee (GEAC) under the Ministry of Environment, Forest and Climate Change grants environmental clearance for large-scale or commercial use of genetically modified organisms. At the institutional level, Institutional Biosafety Committees (IBSCs) monitor biosafety compliance in research laboratories. The Department of Biotechnology (DBT) further supports these mechanisms by framing biotechnology policies and issuing biosafety guidelines4. Together, these agencies form a comprehensive and multi-tiered regulatory framework that governs the development, evaluation, and commercialization of biotechnological products in India, ensuring scientific progress while safeguarding public health. Overview of regulatory requirements of biotechnological products as per CDSCO in India Applicable Guidelines and Regulations of Biologicals in India In India, drugs and biotechnological products are regulated under the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945. Import, manufacture, or marketing of biotechnologicals without a valid license is prohibited. Additionally, the Rules for Hazardous Microorganisms/Genetically Engineered Organisms or Cells, 1989 govern similar biologics. Several guidelines, including the Recombinant DNA Safety Guidelines (1990), Preclinical and Kumar et. al., Am. J. PharmTech Res. 2025;15(05) ISSN: 2249-3387 www.ajptr.com 102 Clinical Data Guidelines for r-DNA Vaccines (1999), and CDSCO Guidance for Industry (2008), outline requirements for clinical trials, approvals, post-approval changes, and quality standards5. Approval Process for Biotechnological Products The approval of novel biotechnologicals involves preclinical and clinical evaluation to establish safety, efficacy, and quality. Manufacturers first submit an Investigational New Drug (IND) application with preclinical and manufacturing data. Clinical trials follow a phased approach Phase I for safety, Phase II for efficacy, and Phase III for confirmation in larger populations. After successful trials, a New Drug Application (NDA) is submitted, which is reviewed by regulatory authorities for market authorization. Preclinical and Clinical Studies Preclinical studies assess pharmacology, pharmacodynamics, toxicity, and immunogenicity using in vitro and in vivo models. Reports must be approved by RCGM, IBSC, and IAEC. Clinical trials confirm pharmacokinetics, efficacy, and safety in humans, often comparing similar biologics with reference products. Regulatory guidance ensures rigorous study design and adherence to ethical and biosafety standards. Post-Market Surveillance Even after approval, biotechnological products undergo pharmacovigilance, including submission of Periodic Safety Update Reports (PSURs) and reporting of serious adverse events. Postmarketing studies (PMS) monitor long-term safety and efficacy, helping detect potential risks early. Quality Control and Manufacturing Quality control is performed at Central Drugs Laboratory (CDL), Kasauli, and the National Institute of Biologicals (NIB), Noida. Both laboratories test and verify biotechnological products before market release. Schedule M of the Drugs and Cosmetics Act defines Good Manufacturing Practices (GMP) for premises, processes, and materials, aligning Indian standards with international guidelines. Regulatory Oversight India’s biotechnology products are regulated through a multi-agency system: IBSCs ensure laboratory biosafety, RCGM oversees preclinical research, GEAC handles environmental approvals, and DCGI/CDSCO grants clinical trial and marketing authorizations. This coordinated system ensures safety from research to commercialization while supporting innovation6. Overview of FDA in USA Kumar et. al., Am. J. PharmTech Res. 2025; 15(05) ISSN: 2249-3387 103 www.ajptr.com The U.S. Food and Drug Administration (FDA) is a federal agency under the Department of Health and Human Services (HHS). It is responsible for protecting public health by ensuring the safety, efficacy, and quality of drugs, biologics, medical devices, food, cosmetics, and radiationemitting products. Established in 1848, the FDA is the federal government’s oldest consumer protection agency and has continually evolved to address emerging health challenges and innovation in regulated industries. The FDA performs multiple functions, including the approval of new drugs, vaccines, and biologics; regulation of food safety, medical devices, cosmetics, dietary supplements, and tobacco products; post-market surveillance; and conducting research to support regulatory decisions. The agency can also issue Emergency Use Authorizations (EUA) during public health crises to allow rapid access to critical products. In the United States, biotechnological products or biologics, such as recombinant proteins, monoclonal antibodies, gene therapies, cell-based therapies, and biosimilars, are regulated separately from conventional drugs due to their complex structures and manufacturing processes. These products are primarily regulated under the Public Health Service (PHS) Act, which requires a Biologics License Application (BLA) for marketing, and the Federal Food, Drug, and Cosmetic (FD&C) Act, which governs safety, labeling, and manufacturing standards. The FDA’s regulatory oversight of biologics is carried out mainly through the Center for Biologics Evaluation and Research (CBER), which handles vaccines, gene therapies, and cell-based products, and the Center for Drug Evaluation and Research (CDER), which regulates therapeutic biotech products such as monoclonal antibodies and enzymes. The Office of Tissues and Advanced Therapies (OTAT) under CBER specifically focuses on cell and gene therapies. The regulatory process for biotechnological products includes preclinical testing, submission of an Investigational New Drug (IND) application, clinical trials, review and approval through BLA, and post-marketing surveillance. All products must meet strict standards for purity, potency, safety, and consistency, and comply with Good Manufacturing Practices (GMP) and Good Clinical Practices (GCP) throughout development and commercialization7. Overview of regulatory requirements of biotechnological products as per FDA in USA In the United States, the regulation of biotechnological products, also known as biologics, is overseen by the U.S. Food and Drug Administration (FDA). This pathway ensures that biologics are safe, effective, and consistently manufactured to high quality standards. The process spans from early preclinical research to post-marketing surveillance8. Kumar et. al., Am. J. PharmTech Res. 2025;15(05) ISSN: 2249-3387 www.ajptr.com 104 Before formal submissions, sponsors conduct extensive preclinical studies on pharmacology, toxicology, and ADME (absorption, distribution, metabolism, and excretion) under Good Laboratory Practice (GLP) standards. Manufacturing processes, production cell lines, purification methods, and quality control assays are established according to current Good Manufacturing Practice (cGMP). Sponsors often consult the FDA in Pre-Investigational New Drug (Pre-IND) meetings to discuss nonclinical findings, CMC strategies, early clinical protocols, and potential regulatory pathways, helping to streamline the development process. To initiate human clinical trials, an Investigational New Drug (IND) application is submitted under 21 CFR Part 312. This includes preclinical safety data, CMC documentation, clinical trial protocols, investigator qualifications, and confirmation of Good Clinical Practice (GCP) and Institutional Review Board (IRB) compliance. The FDA reviews the IND within 30 days, and if no clinical hold is issued, trials may proceed. Sponsors must report adverse events, submit annual progress reports, and update protocols as required. Clinical development proceeds in phases: Phase I assesses safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) in a small cohort; Phase II evaluates preliminary efficacy and dosage optimization in several hundred patients; and Phase III confirms efficacy and safety in large, pivotal studies. All phases follow GCP guidelines, maintain detailed Trial Master Files, and may involve independent Data Safety Monitoring Boards (DSMBs) for higher-risk studies. After successful clinical trials, a Biologics License Application (BLA) is submitted under 21 CFR Parts 600, 601, and 610. The BLA includes all clinical, nonclinical, and CMC data, manufacturing facility information, stability studies, potency assays, and proposed labeling. The FDA reviews the application, inspects manufacturing sites for cGMP compliance, and may consult advisory committees for expert input. Approval results in market authorization, while additional information may be requested through a Complete Response Letter (CRL). Post-marketing surveillance ensures ongoing product safety. Sponsors must comply with Post marketing Requirements (PMRs) and Post marketing Commitments (PMCs), submit periodic safety reports, and maintain pharmacovigilance through systems like MedWatch or VAERS. Risk Evaluation and Mitigation Strategies (REMS) may be required for products with significant safety concerns. Promotional materials must align with FDA-approved labeling, and off-label promotion is strictly prohibited. Special considerations for biotechnological products include temperature-sensitive cold chain logistics, rigorous immunogenicity testing, and compliance with the Biosimilar Approval Pathway Kumar et. al., Am. J. PharmTech Res. 2025; 15(05) ISSN: 2249-3387 105 www.ajptr.com under the Biologics Price Competition and Innovation Act (BPCIA) for products similar to reference biologics9. Kumar et. al., Am. J. PharmTech Res. 2025;15(05) ISSN: 2249-3387 www.ajptr.com 106 Comparative tabulation analysis of CDSCO and US FDA Sl. No Regulatory Parameter India – CDSCO / DBT / RCGM USA – USFDA (CBER / CDER) 1 Regulatory Authority CDSCO (MoHFW), DBT, RCGM, GEAC FDA (CBER for biologics, CDER for biotech drugs), USDA, EPA 2 Legal Framework Drugs & Cosmetics Act, 1940; NDCT Rules, 2019 Public Health Service (PHS) Act; Food, Drug & Cosmetic (FD&C) Act 3 Product Classification Biotechnological products classified as biologicals Biologics under Biologics License Application (BLA) pathway 4 Types of Products Recombinant proteins, monoclonal antibodies, vaccines, gene therapies Same as India + cell therapies, tissue-based products 5 Application Type Clinical Trial Application → Market Authorization Application IND → BLA 6 Dossier Format CTD (Common Technical Document) Modules 1 – 5 ICH CTD Modules 1 – 5 7 Clinical Trial Phases Phase I–III (as per NDCT Rules); Phase IV (optional or conditional) Phase I–III mandatory; Phase IV (post-marketing surveillance) 8 Clinical Trial Approval Form CT - 04, Ethics Committee approval, DCGI review IND submission + IRB approval + FDA clearance 9 GCP Guidelines Indian GCP (based on ICH E6) ICH - GCP + 21 CFR Part 312 10 Preclinical Requirements GLP-compliant studies; DBT & RCGM requirements for rDNA and GMOs GLP studies as per 21 CFR Part 58 11 Manufacturing Requirements WHO - GMP or Schedule M compliance US cGMP – 21 CFR Part 210, 211, 600 – 680 12 Quality Control Standards Indian Pharmacopoeia (IP), WHO GMP US Pharmacopoeia (USP), cGMP 13 Analytical Characterization Required for biosimilars; comparability with reference biologic Detailed analytical similarity required using totality of evidence approach 14 Bioequivalence/Bio similarity Studies Similar Biologics Guidelines (2016, Draft 2022/25) aBLA (Abbreviated BLA); Biosimilar Guidelines 15 Environmental Clearance (GMO) GEAC approval required for GMOs and gene therapy Environmental assessment required; oversight by EPA/USDA 16 Labelling Requirements As per Drugs and Cosmetics Rules 21 CFR Part 201 17 Risk Management Plan (RMP) Mandatory PvPI (Pharmacovigilance Program of India) REMS (Risk Evaluation & Mitigation Strategy) 18 Pharmacovigilance System PvPI; PSUR every 6 months (2 years), then annually FDA MedWatch, FAERS; periodic and expedited AE reports 19 Post - Marketing Surveillance Required by CDSCO; Phase IV studies encouraged Required under REMS/FAERS Kumar et. al., Am. J. PharmTech Res. 2025; 15(05) ISSN: 2249-3387 107 www.ajptr.com 20 Inspection of Manufacturing Sites CDSCO/State FDA inspections FDA Pre-Approval Inspection (PAI) and GMP compliance inspections 21 Regulatory Timelines 12–18 months post clinical trials 12–24 months (standard); shorter for fast-track approvals 22 Fast Track / Priority Pathways Conditional approvals for national health priorities Fast Track, Accelerated Approval, Breakthrough Therapy, Priority Review 23 Orphan Drug Designation Not formalized; NDCT allows certain relaxations for rare diseases Orphan Drug Act (1983); 7-year market exclusivity, fee waivers, tax credits 24 Fees / Cost of Application Relatively low; varies by type of product High under Prescription Drug User Fee Act (PDUFA) 25 Public Access to Regulatory Information Limited; available on CDSCO portal Public databases: Drugs@FDA, Purple Book, ClinicalTrials.gov Kumar et. al., Am. J. PharmTech Res. 2025;15(05) ISSN: 2249-3387 www.ajptr.com 114 [cited 2025 Sep 4]. Available from: URL: https://www.fda.gov/news-events/pressannouncements/epa-fda-and-usda-issue-joint-regulatory-plan-biotechnology 18. Food Dive. Wildtype’s lab-grown salmon receives FDA clearance [Internet]. 2025 Jun 12 [cited 2025 Sep 4]. Available from: URL: https://www.fooddive.com/news/wildtype-labgrown-salmon-fda-clearance/750518 AJPTR is  Peer-reviewed  bimonthly  Rapid publication Submit your manuscript at: edito[email protected]